AzTrials
AzTrials

Multiple MyelomaPhase 1NCT06698744

UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

A Phase 1 study testing UF-KURE-BCMA CAR T-cells, Cyclophosphamide and Fludarabine in people with Multiple Myeloma and Multiple Myeloma in Relapse, run by David Wald at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The purpose of this study is to determine if UF-KURE-BCMA (B-Cell Maturation Antigen) chimeric antigen receptor T cells (CAR-T cells) can be used to treat relapsed or treatment refractory multiple myeloma (RRMM). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
UF-KURE-BCMA CAR T-cells, Cyclophosphamide and Fludarabine
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteUnited States
Study dates
Sep 2025to Sep 2028
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female participants aged 18 years or older.
  • Subjects must have Multiple Myeloma that is relapsed (defined as non-responsive or progressive disease while on therapy or within 60 days of last treatment in participants who had achieved a minimal response (MR) or better on prior therapy) after three or more lines of therapy including at least one proteasome inhibitor, one imide, and one anti-CD38 agent.
  • Participants with multiple myeloma with comorbid amyloid and/or extramedullary disease will be eligible.
  • To be eligible for response assessment, participants must have measurable disease at the time of screening defined as serum protein electrophoresis M-spike greater than or equal to 0.5 g/dl, urine protein electrophoresis M spike greater than or equal to 200 mg/24 hr, or difference in involved free light chain level of greater than or equal to 10 mg/dl provided serum free light chain (FLC) ratio is abnormal.
  • ECOG Performance status ≤ 2
  • Minimum of 2 weeks since prior radiation therapy or systemic therapy to treat malignancy at the time of blood sample collection for CAR-T manufacturing unless treatment was investigational, in which case a minimum of 4 weeks since last treatment is required. Prior CAR-T therapy is acceptable if participants exhibited progression free survival of greater than 6 months post CAR-T infusion.
Show all 14Show fewer
  • Total bilirubin ≤ 2X institutional upper limit of normal (except in participants with Gilbert's syndrome).
  • AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal.
  • Calculated creatinine clearance ≥ 30mL/min estimated by the Cockcroft - Gault formula.
  • Cardiac ejection fraction of ≥45% as determined by an echocardiogram.
  • Adequate pulmonary function, defined as ≤ Grade 1 dyspnea and oxygen saturation (SaO2) ≥ 92% on room air. If pulmonary function tests (PFTs) are performed based on the clinical judgment of the treating physician, participants with forced expiratory volume in 1 second (FEV1) ≥ 50% of predicted and diffusing capacity for carbon monoxide (DLCO) (corrected for hemoglobin) of ≥ 40% of predicted will be eligible.
  • Participants (or legal guardians) must have the ability to understand and the willingness to sign a written informed consent document.
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 6 months after the UF-KUREBCMA CAR-T cell infusion. A woman is considered to be of childbearing potential if she is < 60 years old, postmenarcheal, has not reached a postmenopausal state (< 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the UF-KURE-BCMA CAR-T cell infusion. Men must refrain from donating sperm during this same period. With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the UF-KURE-BCMA CAR-T cell infusion to avoid potential embryonal or fetal exposure. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Who cannot join

  • Autologous stem cell transplant within 6 weeks of informed consent.
  • Active CNS involvement of multiple myeloma.
  • Plasma cell leukemia
  • History of allogeneic hematopoietic stem cell transplantation.
  • Second active malignancy, other than non-melanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast). Stage 1 uterine cancer or localized prostate cancer.
  • New York Heart Association class IV congestive heart failure.
Show all 14Show fewer
  • Cardiovascular disorders including unstable angina pectoris, clinically significant cardiac arrhythmias, myocardial infarction or stroke (including transient ischemic attack, or other ischemic event) within 6 months prior to registration.
  • Known human immunodeficiency virus infection or acquired immunodeficiency syndrome related illness.
  • Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
  • Evidence of myelodysplasia or cytogenetic abnormality indicative of myelodysplasia on the most recent bone marrow biopsy prior to initiation of therapy.
  • Serologic status reflecting active hepatitis B or C infection. Participants that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive participants will be excluded).
  • Participants with history of clinically relevant CNS pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
  • Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
  • History of active autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of systemic immunosuppressive medications other than low dose steroids [i.e. maximum of 15mg prednisone equivalent] within the last 6 months.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University Hospitals Cleveland Medical Center Seidman Cancer Center

    Cleveland, Ohio, 44106

Other trials in United States

About this study

Official title: A Phase 1 Single Arm, Open Label Study to Evaluate the Safety of UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to determine if UF-KURE-BCMA (B-Cell Maturation Antigen) chimeric antigen receptor T cells (CAR-T cells) can be used to treat relapsed or treatment refractory multiple myeloma (RRMM). This treatment uses T cells already present within the body that have been modified outside of the body by a virus and then returned by an infusion to fight cancer. The investigators are evaluating UF-KURE-BCMA because it uses a manufacturing process that is shorter than other Food and Drug Administration (FDA) approved CAR-T cells and only requires a simple blood draw. The standard treatments require weeks to manufacture the cells as well a special procedure to get an individual's cells. While the shorter manufacture time can be an advantage, the safety of this approach has not been demonstrated. The use of UF-KURE-BMCA is investigational and is not approved by the FDA outside of clinical trials. This is the first study of UF-KURE-BCMA in patients.

Participants will give a pint of blood, which is the amount one would provide if they were to donate blood. The blood will be used to make the UF-KURE-BCMA cells. Participants will then receive chemotherapy followed by a one-time infusion of the experimental modified CAR-T cells. After this infusion, participants will be watched for side effects and follow up will continue for up to 15 years.

Read the detailed description

UF-KURE-BCMA is an autologous CAR-T cell therapy consisting of autologous cluster of differentiation 4 (CD4) positive and cluster of differentiation 8 (CD8) positive human T cells that are genetically engineered using a novel ultrafast lentiviral manufacturing system to express a humanized BCMA CAR-T that targets the BCMA receptor to eliminate multiple myeloma cells using simple peripheral blood draws instead of invasive leukapheresis. This ultrafast platform optimizes CAR-T potency and allows for quicker and cheaper manufacturing of these agents. The goal of this phase 1 study is to find recommended phase 2 dose of UF-KURE-BCMA for treatment of patients with relapsed or refractory multiple myeloma

Being tested
UF-KURE-BCMA CAR T-cells, Cyclophosphamide, Fludarabine
Keywords
UF- KURE-BCMA
Medical subject headings
Multiple Myeloma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UF-KURE-BCMA CAR T-cellsBiological

    Also called UF-KURE-BCMA cells

    Experimental anti-BCMA CAR T-cells manufactured with a proprietary ultrafast process. Patients will receive a single dose of CAR T-cells at one of three potential doses:

    • Dose -1: 3x10^6 cells
    • Dose 1: 10x10^6 cells
    • Dose 2: 15x10^6 cells

  • CyclophosphamideDrug

    Patients will receive 3 days of intravenous (IV) cyclophosphamide 500 mg/m^2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.

  • FludarabineDrug

    Patients will receive 3 days of IV fludarabine 30 mg/m2 days -5 to -3 or -4 to -2 where day 0 is the day of CAR T-cell infusion.

Study groups in NCT06698744
Study groupRoleWhat they receive
UF-KURE-BCMA T cell-based immunotherapyExperimentalPre-infusion will include multiple myeloma testing, preCAR-T evaluation, and cells will be collected. Participants will undergo lymphodepletion and inpatient CAR T-cell infusion. Patients will be monitored closely during a 28 day dose limiting toxicity (DLT) period.
Receives: Biological: UF-KURE-BCMA CAR T-cells; Drug: Cyclophosphamide; Drug: Fludarabine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To recommend a phase two cell dose for UF-KURE-BCMA.

    Patients will be enrolled sequentially using a 3+3 design no sooner than every 28 days during the dose escalation phase and monitored for excessive dose limiting toxicities (DLT). If more than one DLT is observed in 6 patients treated, that dose is considered too toxic.

    The following serious adverse events are deemed DLTs. DLTs are graded per CTACAE V5 or ASTCT grading for CRS or ICANS.

    • Any death unless due to disease progression
    • Grade 4 CRS.
    • Grade 3 CRS that does not improve to ≤ grade 2 in 72 hours after treatment.
    • Grade 3 or higher ICANS.
    • Grade 4 neutropenia or thrombocytopenia that does not improve to ≤ Grade 2 within 42 days. Grade 3 thrombocytopenia with clinically significant bleeding.
    • Grade 3 or higher organ toxicity of any duration (Exception Grade 3 or 4 abnormal hepatic or renal function tests that improve to ≤ Grade 2 within 7 days).
    • All other Grade 3 toxicities, not attributable to disease or chemo that do not resolve to ≤ Grade 2 within 72 hours.

    Measured: 28 days

  2. Incidence of trial stopping rule event

    In the event of any of the following, study enrollment will be suspended pending safety review.

    1. Any treatment-related death (Grade 5 event) that occurs following treatment with UF-KURE-BCMA T cells and not related to disease progression.
    2. Unexpected severe toxicities such as
    3. Occurrence of Grade 4 DLTs in 2 subjects at the same dose level.
    4. Uncontrolled CAR T cell proliferation requiring CAR T cell ablation.
    5. Grade 4 neurotoxicity with cerebral edema.
    6. New malignancy distinct from recurrence/progression of previously treated malignancy and at least possibly related to IP.
    7. Replication-competent lentivirus (RCL) detection in any subjects.

    To re-initiate study enrollment, the sponsor and principal investigator will submit a study reactivation plan to the Food and Drug Administration for approval, including additional safeguards to prevent and minimize subsequent adverse events.

    Measured: 28 days

Secondary outcomes (5)

  1. Clinical responses of RRMM patients treated with UF-KURE-BCMA.

    Clinical response will be defined by International Myeloma Working Group (IMWG) consensus response criteria using MM disease serologies, % bone marrow plasma cells, and next-generation sequencing MRD testing obtained at 30, 60, and 90 days post CAR-T infusion.

    Measured: 90 days

  2. Median duration of response (DOR) in RRMM patients treated with UF-KURE-BCMA.

    DOR will be defined as the time in months from the deepest clinical response as defined by IMWG criteria until disease progression or death, whichever comes first. Median DOR is the time at which 50% of patients have progressed.

    Measured: 2 years

  3. Progression-free survival (PFS) in RRMM patients treated with UF-KURE-BCMA.

    Progression free survival will be defined as the time from enrollment until either disease progression or death, which ever comes first. Median PFS will be defined as the time in months at which 50% of patients exhibit progressive disease or have died.

    Measured: 2 year

  4. Feasibility of manufacturing UF-KURE-BCMA using peripheral blood.

    Peripheral manufacturing of CAR T-cells from peripheral blood will be deemed feasible if the produced CAR T-product meets release criteria in 75% or more cases.

    Measured: 1 week

  5. Overall survival (OS) in RRMM patients treated with UF-KURE-BCMA.

    OS will be defined as the time from enrollment until death. Median OS will be defined as the time from enrollment in months at which 50% of patients have died.

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2024
  2. Study startSep 2025 (estimated)
  3. Primary completion11 Dec 2026 (estimated)
  4. Study completionSep 2028 (estimated)

Why it stopped: Replaced by study by different sponsor

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Phase 1 single arm, open label study
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06698744
Sponsor's protocol ID
CASE1A24
Status last verified
Jan 2026
First submitted
7 Nov 2024
Last updated
13 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Protocol, SAP and CSR will be shared.

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing UF-KURE-BCMA CAR T-cells, Cyclophosphamide and Fludarabine in people with Multiple Myeloma and Multiple Myeloma in Relapse, run by David Wald at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To recommend a phase two cell dose for UF-KURE-BCMA. (time frame: 28 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06698744.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in